You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿斯利康疫苗风险惹关注 澳洲加码采购2,000万剂辉瑞疫苗
阿思达克 04-09 13:08
在澳洲卫生部预警阿斯利康(AZN.US)疫苗与血栓存潜在关连,决定向50岁以下国民推荐辉瑞(PFE.US)疫苗後,外电报道,澳洲联邦政府修订新冠疫苗采购计划,额外增购2,000万剂辉瑞疫苗。总理莫里逊指额外采购後,澳洲今年将共购入4,000剂辉瑞疫苗;料额外增购的2,000万剂疫苗将於末季运抵澳洲。现时仅100万剂辉瑞疫苗已付运至澳洲。

该国至今仅一名44岁男子在接种疫苗後出现血栓。莫里逊就阿斯利康疫苗安抚国民,重覆指不会禁止阿斯利康疫苗,并预期数以百万计国民将接种该款疫苗;他表示,阿斯利康疫苗适合用於重点须受保护团体。

由於辉瑞疫苗采用mRNA技术,未能在当地生产或分发,完全依赖进口。而大部分澳洲国民料接种阿斯利康疫苗,因澳洲有能力在本国生产。采购共4,000剂辉瑞疫苗,料足以为2,000万国民接种,因每人须接种两剂疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account